Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The relationship between IL6 and the kinetics of the ApoB-containing Lipoproteins in people with chronic inflammatory joint disease.

Next Previous
Trial Profile

The relationship between IL6 and the kinetics of the ApoB-containing Lipoproteins in people with chronic inflammatory joint disease.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Sep 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tocilizumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Pharmacodynamics
  • Acronyms apoB Kinetics; KALIBRA

Most Recent Events

  • 15 Sep 2017 Primary endpoint of change in fractional catabolic rate of LDL-associated apolipoprotein has been met, according to results published in the Annals of the Rheumatic Diseases.
  • 15 Sep 2017 Results published in the Annals of the Rheumatic Diseases
  • 12 Dec 2014 Planned End Date changed from 19 Apr 2015 to 11 Dec 2014 as reported by United Kingdom Clinical Research Network.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top